Kidney Cancer Trial Results
Denosumab Effective for Multiple Myeloma and Solid Tumors
(Posted: 06/08/2011) - Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).
When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
Sorafenib Delays Progression of Metastatic Kidney Cancer
(Posted: 02/07/2007, Updated: 06/08/2009) - The targeted drug sorafenib (Nevaxar®), which delays disease progression in patients with metastatic kidney cancer, may also improve survival of such patients, according to the May 18, 2009, Journal of Clinical Oncology.
Everolimus Extends Progression-Free Survival in Advanced Kidney Cancer
(Posted: 07/30/2008) - A phase III trial testing the drug everolimus in patients with advanced kidney cancer was stopped after an interim analysis showed a significant improvement in progression-free survival, the drug's manufacturer, Novartis, reported February 28, 2008.
Sorafenib Increases the Risk of High Blood Pressure
(Posted: 04/02/2008) - Combined data from nine studies showed that patients receiving the standard amount of sorafenib (Nexavar®), an anticancer drug that interferes with a tumor's blood supply, run a significant risk of high blood pressure (hypertension), according to the February 2008 Lancet Oncology.
(Posted: 06/08/2011) - Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).
When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
Sorafenib Delays Progression of Metastatic Kidney Cancer
(Posted: 02/07/2007, Updated: 06/08/2009) - The targeted drug sorafenib (Nevaxar®), which delays disease progression in patients with metastatic kidney cancer, may also improve survival of such patients, according to the May 18, 2009, Journal of Clinical Oncology.
Everolimus Extends Progression-Free Survival in Advanced Kidney Cancer
(Posted: 07/30/2008) - A phase III trial testing the drug everolimus in patients with advanced kidney cancer was stopped after an interim analysis showed a significant improvement in progression-free survival, the drug's manufacturer, Novartis, reported February 28, 2008.
Sorafenib Increases the Risk of High Blood Pressure
(Posted: 04/02/2008) - Combined data from nine studies showed that patients receiving the standard amount of sorafenib (Nexavar®), an anticancer drug that interferes with a tumor's blood supply, run a significant risk of high blood pressure (hypertension), according to the February 2008 Lancet Oncology.
